The recent recommendation from the U.S. Department of Health and Human Services (HHS) to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA) has sparked much debate and discussion. However, a new report from the Congressional Research Service (CRS) offers insights into the potential legal consequences of this proposed change.
The Congressional Research Service is a nonpartisan research organization that provides information and analysis to Congress. Their report delves into the complexities of marijuana’s current Schedule I classification and the potential impact of moving it to Schedule III.
Marijuana has been a highly debated and controversial topic for decades, with its use being prohibited at the federal level under the Controlled Substances Act since 1970. However, in recent years, many states have taken steps to legalize marijuana for medical or recreational use.
Despite these state efforts, marijuana remains illegal at the federal level, creating discrepancies between state and federal laws. This has led to increased confusion and uncertainty surrounding the legal status of marijuana, especially for those involved in state-legal medical and recreational markets.
Legal Consequences of Rescheduling Marijuana from Schedule I to Schedule III Per CRS
The CSA classifies drugs into five schedules based on their potential for abuse, medical value, and safety. Schedule I is reserved for the most dangerous and highly addictive substances with no accepted medical use, while Schedule III includes drugs with moderate potential for abuse and currently accepted medical uses.
Rescheduling marijuana from Schedule I to Schedule III would acknowledge its potential medical value, potentially opening the door for further research and FDA approval of prescription marijuana products. However, it could also create challenges for state-legal markets and the regulation of cannabis products.
“Moving marijuana from Schedule I to Schedule III, without other legal changes, would not bring the state-legal medical or recreational marijuana industry into compliance with federal controlled substances law.” the CRS report says.
“With respect to medical marijuana, a key difference between placement in Schedule I and Schedule III is that substances in Schedule III have an accepted medical use and may lawfully be dispensed by prescription, while Substances in Schedule I cannot. However, prescription drugs must be approved by the Food and Drug Administration (FDA). Although the FDA has approved some drugs derived from or related to cannabis, marijuana itself is not an FDA-approved drug.”
“Moreover, if one or more marijuana products obtained FDA approval, manufacturers and distributors would need to register with DEA and comply with regulatory requirements that apply to Schedule III substances in order to handle those products. Users of medical marijuana would need to obtain valid prescriptions for the substance from medical providers, subject to federal legal requirements that differ from existing state regulatory requirements for medical marijuana.”
The Congressional Research Service report also highlights the fact that Congress has granted states some flexibility in their approach to medical marijuana. Since 2014, a budget rider has been passed every year, prohibiting the Department of Justice from using federal funds to interfere with state laws allowing for the distribution and use of medical marijuana.
This appropriations rider serves as a temporary protection against federal prosecution for state-legal activities involving medical marijuana. However, it does not fully remove the threat of criminal liability and only applies to medical marijuana, not recreational marijuana.
Despite this, recent presidential administrations have generally not prioritized prosecution of state-legal activities involving marijuana. This has allowed states to continue implementing their own laws and regulations surrounding medical marijuana without fear of federal interference.
However, the report also notes that the Constitution’s Supremacy Clause dictates that federal law takes precedence over conflicting state laws. This means that even with state laws in place, marijuana is still considered a Schedule I controlled substance under the CSA, and unauthorized activities involving marijuana are still federal crimes.
Nonetheless, this leeway granted by Congress has allowed for the expansion of medical marijuana programs in many states, providing relief and alternative treatment options for patients in need. It also highlights the growing acceptance and changing attitudes toward marijuana use, potentially paving the way for further rescheduling or legalization efforts in the future.
So, while federal law still classifies marijuana as a dangerous substance, the actions of Congress show a shift towards recognizing its potential medical benefits and allowing states to make their own decisions regarding
Potential Changes in Penalties and Taxation for Marijuana Offenses
The rescheduling of marijuana to Schedule III could also have significant implications for penalties and taxation related to its use. As a Schedule I drug, possessing even small amounts of marijuana can result in severe federal criminal charges. However, moving it to Schedule III may reduce penalties for certain offenses.
“With respect to the manufacture, distribution, and possession of recreational marijuana, if marijuana were moved to Schedule III, such activities would remain illegal under federal law and potentially subject to federal prosecution regardless of their status under state law.
“Some criminal penalties for CSA violations depend on the schedule in which a substance is classified. If marijuana were moved to Schedule III, applicable penalties for some offenses would be reduced. However, CSA penalties that apply to activities involving marijuana specifically, such as the quantity-based mandatory minimum sentences discussed above, would not change as a result of rescheduling. DEA is not required to set annual production quotas for Schedule III controlled substances.”
Additionally, a Schedule III classification for marijuana could also lead to changes in the taxation of cannabis products. Currently, state-legal marijuana businesses face high tax rates due to federal restrictions on the substance. However, a Schedule III classification may bring some relief in this area.
“The prohibition on business deductions in Section 280E of the Internal Revenue Code applies to any trade or business that “consists of trafficking in controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted.”
“Because the provision applies only to activities involving substances in Schedule I or II, moving marijuana from Schedule I to Schedule III would allow marijuana businesses to deduct business expenses on federal tax filings. Other collateral legal consequences would continue to attach to unauthorized marijuana-related activities.”
Congress Considerations From Report
The report from the Congressional Research Service on the “legal consequences” of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) presents various considerations for Congress to take into account.
First and foremost, it is important for Congress to understand its authority and role in changing the legal status of marijuana under the CSA. While the DEA has the power to make scheduling decisions through rulemaking, Congress also has the authority to change the status of a controlled substance through legislation. In fact, some proposals from the 118th Congress would provide for congressional review of DEA’s rescheduling decisions related to marijuana. As such, it is crucial for lawmakers to carefully consider any potential changes to the legal status of marijuana and their implications.
Another consideration outlined by the report is how rescheduling or descheduling marijuana could impact FDA regulation of certain cannabis products under the Federal Food, Drug, and Cosmetic Act. If marijuana were moved to Schedule III through legislation, Congress may need to address how the FDA regulates these products or potentially create a new regulatory framework. This could also have implications for the United States’ international treaty obligations.
Furthermore, Congress should consider the potential changes in penalties and taxation that could result from marijuana rescheduling. As the report notes, moving marijuana from Schedule I to Schedule III would allow businesses in the industry to deduct business expenses on federal tax filings. This could bring relief to businesses that currently face high tax rates due to federal restrictions on marijuana. However, other collateral legal consequences may still apply to marijuana-related activities.
In addition, Congress should also consider whether they wish to impose more stringent controls on marijuana, as opposed to relaxing federal regulation. Some proposals from the 117th Congress sought to address issues such as workplace impairment and driving under the influence of marijuana and other substances. Lawmakers may also consider prohibiting the use of certain federal funds or benefits for states that have legalized recreational marijuana.
Overall, the potential rescheduling of marijuana under the CSA brings forth many considerations for Congress to take into account. From understanding their authority in making such changes to addressing potential impacts on FDA regulations and penalties/taxation, there are various factors that must be carefully considered before taking any action.
At Beard Bros, we believe that fully descheduling cannabis under the CSA would be the best move for marijuana businesses and legalization efforts. This would remove any confusion or conflicts between state and federal laws, allowing for a smoother and more streamlined industry.
Ultimately, it is up to Congress to carefully weigh all of these considerations and make well-informed decisions regarding the legal status of marijuana. Our hope is that through responsible legislation, we can create a more fair and equitable system for the cannabis industry and those who rely on it.
Keep updated on all the latest news and updates in the Cannabis industry here at Beard Bros Pharms by signing up for our Friday Sesh Newsletter here. Always Dank and Never Spam!
